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282 Annual respiratory assessment and re-education of CF patients
and families, a quality improvement project
P. Ratkiewicz1, A. Filbrun1, S.Z. Nasr1. 1University of Michigan, Ann Arbor,
United States
Goal: To develop annual standardized respiratory assessment tool to improve care.
Methods: A respiratory assessment (ARA) tool was developed. Patients/families
were asked about CF knowledge, medication action, airway clearance and proper
device cleaning. They were asked to bring all equipment to the assessment. It
took about 40 minutes to complete. During the session, the Respiratory Therapist
reviewed airway clearance techniques, equipment ﬁt, settings and cleaning/use of
equipment and inhaled medications. The family was assisted with replacement
of any equipment, as indicated. Contact with homecare and DME suppliers was
facilitated. A CF respiratory guidebook was developed and given to families
at the end of the session. It includes basic information about day to day care,
airway clearance techniques, nebulizers, disinfecting, and contact information. The
ARA form is reviewed and signed by the pulmonologist and saved in patient’s
record.
Results: 70 assessments were completed to date. 65% of those assessed reported
doing prescribed airway clearance almost every day. Of those that were old enough
to cough or “huff cough” 60% reported not knowing the importance of cough/
huff with airway clearance techniques. Only 52% had proper cleaning technique.
80% used the correct order of therapy, and 75% used the correct nebulizer for the
correct medication. 70% were able to articulate the action of each medication.
Discussion: Patients with CF have a complex treatment regimen. Knowledge gaps
were identiﬁed and addressed in a standardized fashion for patients and families.
The next step will be to measure satisfaction and change in knowledge and behavior
on a regular basis.
283 Sizing and ﬁnancing multidisciplinary resources for CF care in
the French healthcare system
G. Rault1, G. Bellon2, D. Pougheon Bertrand3, F. Kletz4, J.-C. Moisdon4. 1Centre
de Perharidy, CF Centre, Roscoff Cedex, France; 2CHU de Lyon, CF Centre,
Lyon, France; 3Dominique Bertrand Conseil, Rueil-Malmaison, France; 4Ecole
Nationale Superieure des Mines Paris, Paris, France
Since newborn screening generalization in 2002, CF care has been organized in
49 French CF centres. However, the initial funds were partially paid, most of
adult centres did not receive their quota. An audit was ordered in 2008 by the
health ministry to evaluate the CF care organization. The survey concluded it was
successful regarding patients registration and safety, but that most centres were
overbooked.
Objectives:
i. Describe and quantify activities carried out by professionals for outpatient care
in 8 CF centres (960 patients)
ii. Determine the fare price for outpatient care and ﬁnd the right coding of
outpatient visit that allows to recover the payment.
Methods:
i. Develop a model of activities for outpatient care
ii. Record the time for each activity performed by each professional for each
patient over a period of 2 weeks; analyse the results by centre, for all centres
and separately for pediatric and adult centres
iii. Put the results into perspective with the CF activity National Database
Conclusions:
i. Time spent by the various professionals for outpatient care activities has been
captured, though conditioned by the resources actually available in the centres.
ii. Observations: 2/3 of patients received care or follow-up during the 2 weeks;
outpatient visit average number is 6 per year; 60% of the professional’s time
was spent for follow-up between the outpatient visits; most of the time was
spent by MD (20%), Nurse (29%) and physiotherapist (11%); time spent for an
adult was 40% less than time spent for a child.
iii. Recommendation: using the speciﬁc coding of CF outpatient visit called
“Day Hospital” would allow a better coverage of cost.
284 The “Railroad Train Project”, a new educational tool (ET) for
parents of CF newborn screened (NBS) infants
E. Carde1, A. Munck1. 1Hoˆpital Robert Debre´, CF Centre, Paris, France
NBS enables early multidisciplinary care which relies on a partnership between
parents (P) and the CF team.
Aim: To create an ET enabling P after a painful diagnosis phase, to recover an
active role in “drawing up and constructing a project with their child” during the
ﬁrst year of life.
Method: An educational diagnosis (with a taped interview) was performed which
concentrated on: family life details, child’s care organization, P reaction to the
announcement of CF, knowledge on CF, their concerns and future plans. This was
followed by a meeting during which a project was drawn up and constructed steps
by steps.
Results: Four families were approached and agreed to participate. The initial
interview and the analysis of P needs showed common knowledge about CF,
adaptation to the illness consequences in various ways; all P shared the capacity
to look to the future. The session entitled “Drawing up and building a project”
enabled the P to make a list of their speciﬁc skills, identify their personal capacities
and outside support system, pinpoint problems and plan steps for carrying out the
project. A new ET entitled “the railroad (RR) train” was created: RR “tracks”
with departure and arrival train stations illustrating the bottoms of the program;
the RR tracks are marked by steps needed to carry out the project. P and their
trainers are to reach an agreement on the different objectives, thereby enabling the
P, as “actors” in the project, to create their own plan for learning about the illness
and confronting it.
Conclusion: Education is a continual process; the fact that it is based on a concrete
project should enhance the learning process by anchoring it in reality.
285 Pharmacokinetics of tobramycin nebulizer solution (Bramitob®)
administered by Pari e-Flow Rapid vs Pari LC Plus nebulizer
in patients with cystic ﬁbrosis and Pseudomonas aeruginosa
infection
M. Govoni1, G. Poli1, H. Cicirello2, D. Santoro3, D. Acerbi1, J. Ruzˇicˇka4. 1Chiesi
Farmaceutici S.p.A, Clinical Pharmacology, Parma, Italy; 2Chiesi Pharmaceuticals
Inc., Rockville, United States; 3Chiesi Farmaceutici S.p.A, Statistics and Data
Management, Parma, Italy; 4Fakultna´ Nemocnica s Poliklinikou, Bratislava,
Slovakia
Objectives: New generation nebulizers are increasingly used to reduce the time
required for inhalation, potentially improving patient compliance. The aim of
this study was to compare the pharmacokinetic proﬁle of tobramycin nebulizer
solution (TNS) 300mg/4mL administered with the Pari e-Flow rapid nebulizer vs
the Pari LC Plus nebulizer coupled with the Pari TurboBOY N compressor.
Methods: Randomized, open label, multicentre, two-period, crossover trial, en-
rolling 27 Cystic Fibrosis (CF) patients aged 18 years, with chronic Pseudomonas
aeruginosa (Pa) infection and FEV1 30% of predicted normal. Patients received
two twice-daily, 28-day treatment periods with TNS delivered by the e-Flow rapid
or LC Plus nebulizer, separated by a 4-week wash-out. Blood and sputum samples
were collected during the ﬁrst 12 and 8 hours post dose, respectively, at day 1 and
day 28. Primary endpoints were plasma tobramycin maximum concentration (Cmax)
and area under the curve (AUC0−t) on day 28.
Results: 27 patients were randomized and 25 completed the study. Patients were
18−47 (mean 25.5) years old. On Day 28, the geometric mean ratios (e-Flow rapid/
LC Plus) for plasma tobramycin Cmax and AUC0−t were 0.85 (90%CI 0.61–
1.19) and 0.87 (90%CI 0.65–1.18), respectively, while the geometric mean ratios
for sputum tobramycin Cmax and AUC0−t were 1.40 (90%CI 0.86–2.27) and
1.38 (90%CI 0.81–2.35), respectively. Mean nebulization time was statistically
signiﬁcantly shorter for the e-Flow.
Conclusion: Plasma and sputum pharmacokinetic data support comparable pul-
monary delivery of TNS in patients using different nebulizers, indicating broad
utility in the clinical management of CF.
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